Pulmonary Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are over 18 years old
- People who have signed a consent form agreeing to take part in the study and to how their personal data will be handled
- People who had an episode of acute pulmonary embolism (a blood clot in the lungs) between 3 and 12 months ago and are currently on blood-thinning medication, AND who fall into one of the following two groups:
Group 1 – People with breathing difficulties:
- People who developed new or ongoing shortness of breath after their blood clot episode (at a moderate level or worse), or whose breathing has gotten noticeably worse compared to before the episode
Group 2 – People without breathing symptoms but with at least one of the following risk factors:
- Ultrasound of the heart showed signs of severely high blood pressure in the lung arteries at the time of the blood clot diagnosis
- A blood condition called antiphospholipid syndrome with all three specific markers present in blood tests
- A long-term intravenous line or a heart pacemaker/defibrillator device that has become infected
- A tube (called a ventriculoatrial shunt) placed in the body to treat a fluid build-up in the brain called hydrocephalus
- A long-term bowel condition such as ulcerative colitis or Crohn's disease
- A history of having the spleen removed
- A blood disorder affecting the bone marrow (such as conditions that cause overproduction of blood cells)
- A long-term bone infection called chronic osteomyelitis
Who may not be able to join:
- People who do not agree to take part in the study
- People who have medical reasons that prevent them from receiving the treatment being studied (confirm specific contraindications with the trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pavel Jansa, prof., General University Hospital of Prague
Phone: 604603143
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Positive predictive value of initial examination; CTEPH detection rates; Proportion of people with suspected CTEPH who attended a follow-up examination at a specialized pulmonary hypertension treatment centre
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.